Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $164 | $1 | $0 | $0 |
| % Growth | 13,699% | – | – | – |
| Cost of Goods Sold | $124 | $11 | $0 | $0 |
| Gross Profit | $40 | -$10 | $0 | $0 |
| % Margin | 24.4% | -804.5% | – | – |
| R&D Expenses | $282 | $344 | $295 | $259 |
| G&A Expenses | $0 | $0 | $104 | $84 |
| SG&A Expenses | $153 | $107 | $104 | $84 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $435 | $451 | $399 | $343 |
| Operating Income | -$395 | -$461 | -$399 | -$343 |
| % Margin | -240.9% | -38,735% | – | – |
| Other Income/Exp. Net | $20 | $13 | $3 | $0 |
| Pre-Tax Income | -$375 | -$448 | -$396 | -$342 |
| Tax Expense | -$3 | -$3 | $0 | $0 |
| Net Income | -$372 | -$444 | -$396 | -$342 |
| % Margin | -226.8% | -37,345.4% | – | – |
| EPS | -1.28 | -1.89 | -2.49 | -2.23 |
| % Growth | 32.3% | 24.1% | -11.7% | – |
| EPS Diluted | -1.28 | -1.89 | -2.49 | -2.23 |
| Weighted Avg Shares Out | 290 | 235 | 159 | 153 |
| Weighted Avg Shares Out Dil | 290 | 235 | 159 | 153 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $13 | $3 | $0 |
| Interest Expense | $0 | $0 | $3 | $0 |
| Depreciation & Amortization | $44 | $33 | $21 | $14 |
| EBITDA | -$352 | -$427 | -$378 | -$329 |
| % Margin | -214.3% | -35,948.9% | – | – |